Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Sorrento Therapeutics, Inc.
  6. Summary
    SRNEQ   US83587F2020

SORRENTO THERAPEUTICS, INC.

(SRNEQ)
  Report
Delayed OTC Markets  -  03:58:57 2023-06-05 pm EDT
0.3168 USD   +7.35%
05/15Sorrento Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
05/14Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts
PR
04/25Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Otc Markets
05/30/2023 05/31/2023 06/01/2023 06/02/2023 06/05/2023 Date
0.30475(c) 0.3113(c) 0.312(c) 0.2951(c) 0.3168 Last
2 435 527 478 302 1 643 407 949 399 1 479 086 Volume
+5.82% +2.15% +0.22% -5.42% +7.35% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 37,8 M - -
Net income 2023 -263 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,53x
Yield 2023 -
Sales 2024
Net income 2024
Net Debt 2024
P/E ratio 2024
Yield 2024
Capitalization 160 M 160 M -
Capi. / Sales 2023 4,25x
EV / Sales 2024
Nbr of Employees 949
Free-Float 83,6%
More Financials
Company
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library... 
Read more
More about the company
All news about SORRENTO THERAPEUTICS, INC.
05/15Sorrento Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/14Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividen..
PR
04/25Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of S..
PR
04/20Sorrento Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/17Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders
AQ
04/10SORRENTO THERAPEUTICS, INC. Other Events, Financial Statements and Exhibits (form 8-K/..
AQ
04/10Sorrento Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
04/04Sorrento Therapeutics, Inc.'s Bankruptcy Court Requires Brokerages to Provide Informati..
PR
03/31Sorrento Therapeutics, Inc. : Entry into a Material Definitive Agreement, Regulation FD Di..
AQ
03/29Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Pos..
PR
03/28Scilex Holding Company Reports Substantial Underreporting of More Than 44 Million Share..
AQ
03/20Sorrento Therapeutics, Inc. : Other Events, Regulation FD Disclosure, Financial Statements..
AQ
03/17Court Confirms Sorrento Therapeutics, Inc.'s $125 Million Arbitration Award Against Nan..
PR
03/16SORRENTO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
03/16Sorrento Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
CI
More news
News in other languages on SORRENTO THERAPEUTICS, INC.
05/15Sorrento Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
03/16L'auditeur de Sorrento Therapeutics, Inc. L'auditeur émet des doutes sur la continuité ..
03/08Scilex Holding choisit CH Trading Group pour distribuer ZTlido au Moyen-Orient et en Af..
02/22Sorrento Therapeutics reçoit l'approbation du tribunal pour un financement de 75 millio..
02/22Principaux gagnants du pré-marché
More news
Analyst Recommendations on SORRENTO THERAPEUTICS, INC.
More recommendations
ETFs positioned on SORRENTO THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
CI Bio-Revolution ETF - CAD1.28%0.22%-NC
Global X Genomics & Biotechnology ETF - USD0.69%3.23%NC
Global X Genomics & Biotechnology - USD0.69%2.66%-NC
SPDR S&P Biotech ETF - USD0.46%2.51%United_States
VanEck Genomics and Healthcare Innovators - USD0.16%3.64%-NC
More ETFs positioned on SORRENTO THERAPEUTICS, INC.
Chart SORRENTO THERAPEUTICS, INC.
Duration : Period :
Sorrento Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SORRENTO THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,30 $
Average target price 13,00 $
Spread / Average Target 4 305%
EPS Revisions
Managers and Directors
Henry H. Ji Chairman, President & Chief Executive Officer
Elizabeth Adkins Czerepak Chief Financial & Business Officer, Executive VP
Mike A. Royal Chief Medical Officer
Shawn Sahebi Senior Vice President-Commercial Operations
Yue Wu Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SORRENTO THERAPEUTICS, INC.0.00%160
VERTEX PHARMACEUTICALS INCORPORATED15.58%85 966
REGENERON PHARMACEUTICALS, INC.2.56%79 256
WUXI APPTEC CO., LTD.-16.25%28 067
BIONTECH SE-28.02%26 058
GENMAB A/S-7.45%25 588
Secure and increase the performance of your investments with our team of experts at your side.
Securing my Investments
fermer